Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 44Active not recruiting 20Not yet recruiting 10Terminated 4Completed 4Suspended 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Recurrence 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytopenia 1Sinusitis 1Rib Fractures 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Leukemia 1Glioblastoma 1Desmoid Tumors 1Cytopenia 1Communication Disorders 1Colorectal Neoplasms 1

Interventions

vocimagene amiretrorepvec 1Temozolomide 1Radiotherapy 1Radiation 1DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Glioblastoma × 30 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡